scott.pritchett

Since the FDA approvals of Kymriah and Yescarta in 2017, more than 10 autologous CAR-T therapies have been approved globally to treat B-cell lymphoma and multiple myeloma. More recently, new modalities, such as TCR-T for synovial sarcoma and TIL therapies for advanced melanoma, have also received FDA approval. Despite these remarkable therapeutic achievements, CAR T-cell treatments face significant challenges, including systemic toxicities, limited applications in hematologic cancers, and complex, expensive manufacturing processes.

To address these challenges, transitioning CAR-T manufacturing from an autologous approach to an allogeneic approach is essential. Allogeneic manufacturing eliminates patient-specific steps such as lympho-depletion, blood collection, personalized CAR-T production, and QC testing. This streamlined method not only dramatically shortens the treatment process but also ensures timely delivery, reducing the risk of manufacturing failure due to poor quality or insufficient immune cells from individual patients. This transition holds the potential to enhance scalability, improve success rates, and significantly reduce the overall cost of CAR-T therapies. The following figure illustrates the comparison between autologous and allogeneic CAR-T cell therapies.

Advancing Allogeneic Therapies Through Gene Editing

While early attempts at allogeneic immune cell therapies for cancer struggled with issues such as poor persistence after transfusion, advancements in gene editing present a promising solution. For autoimmune diseases, allogeneic universal CAR-T therapies have demonstrated efficacy across multiple indications, such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), severe myositis, and systemic sclerosis (SSc). Engineering these therapies involves multiplex genome editing, often requiring simultaneous gene knockouts and knock-ins, which can now be achieved more efficiently using non-viral processes, reducing costs and minimizing safety risks.

During therapy design, CMC optimization, and clinical validation processes, new gene editing tools supporting the simultaneous modification of multiple genetic targets are being developed. These advancements enable identification of novel targets to prevent CAR-T exhaustion, enhance persistence, and improve adaptation within the tumor microenvironment through functional genomics screening studies and comprehensive sequencing of edited cells. These tools will support the creation of universal allogeneic CAR-T therapies. With continuous improvement, these therapies could eventually replace autologous CAR-T treatments for hematologic cancers and solid tumors.

Optimizing CAR-T Persistence and Precision

A key strategy to prevent CAR-T exhaustion is moderating the density of CAR expression on T cells by controlling the insertion copy number per cell and the expression levels of each CAR gene. Using CRISPR-HDR technology, the CAR sequence can be precisely inserted into the desired reading frame with one or two copies per cell, driven by the endogenous promoter for optimal expression. Recent advancements, such as Cas-targeting sequence (CTS) modifications for CRISPR nucleases like Cas9 and Cas12, have further improved HDR efficiency. Innovative methods like SLEEK (Selection by Essential-gene Exon Knock-in) and SEED (Synthetic Exon/Expression Disruptors) leverage advanced counter-selection strategies to achieve nearly 90% purity in engineered CAR-positive T cells in final therapeutic products, meeting standards for drug purity and homogeneity.

Design Innovations to Improve Potency and Minimize Side Effects

Functionality by design, akin to Quality by Design principles, is rapidly evolving and is critical for delivering next-generation CAR-T therapies. Third-generation CAR-T therapies demonstrate superior proliferation and persistence in vivo compared to second-generation counterparts. The co-stimulatory domains within CAR constructs significantly affect the metabolism and fate of CAR-expressing T cells. For example, the 4-1BB co-stimulatory domain has been shown to provide superior cytokine release while mitigating T-cell exhaustion triggered by scFv-induced CAR aggregation and tonic signaling. Advanced CAR designs incorporating one or more highly sensitive and specific binding domains, combined with the appropriate co-stimulatory domains and even regulatory logic switches, can balance potency and persistence to deliver more effective therapies with reduced side effects. These complex CAR designs can be introduced into T cells via non-viral, targeted genomic editing methods.

By combining advanced gene editing tools into an integrated workflow, researchers can efficiently generate powerful antigen-specific treatments with enhanced persistence during therapy. Leveraging therapeutic designs using healthy donor-derived immune cells enables large-scale manufacturing with improved editing efficiency and enhanced cell proliferation rates. Ultimately, this approach can significantly reduce the per-patient cost of CAR-T and other gene therapies while ensuring faster and more effective treatments. Eliminating lengthy manufacturing waiting times also allows patients to access therapies earlier, preventing further progression of malignant cancers.

Learn more about our CRISPR gene editing solutions here.

Note from the editor: If you have any questions about this blog or other interesting topic suggestions related to gene editing or gene and cell therapy for future posts, please reach out at [email protected].